Experience

To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.

Filters

NuVasive, Inc. $650 Million Notes Offering

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. (“NuVasive”) of $650 million aggregate principal amount of its 2.25% convertible senior…

Pfizer Inc. $5 Billion Accelerated Share Repurchase

Davis Polk advised the counterparty in connection with an accelerated share repurchase transaction entered into between the counterparty and Pfizer Inc. (“Pfizer”), pursuant to which Pfizer…

Quotient Limited Follow-On Offering

Davis Polk advised the sole underwriter in connection with the SEC-registered follow-on public offering of 4,444,445 ordinary shares sold by Quotient Limited (“Quotient”). Total gross…

Biotie acquisition by Acorda

Davis Polk is advising Biotie Therapies Corp. in connection with its combination agreement with Acorda Therapeutics, Inc. where Acorda will make a public tender offer in Finland and the…

Ardelyx, Inc. Common Stock Offering

Davis Polk advised the joint book-running managers in connection with an $86.2 million SEC-registered follow-on common stock offering of 8,625,000 shares of common stock for Ardelyx, Inc…

Adamas Pharmaceuticals, Inc. Common Stock Offering

Davis Polk advised the joint book-running managers in connection with a $66.1 million SEC-registered common stock offering of 2,875,000 shares of common stock of Adamas Pharmaceuticals, Inc…
Back to top